BioLineRx (BLRX) Misses Q2 EPS by 4c

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth